Recently, numerous A-listed companies in China have released their 2024 interim earnings forecasts, with several stocks drawing significant market attention due to explosive year-over-year net profit growth. According to the latest disclosures, three stocks are projected to report net profit increases exceeding 1,000% (i.e., more than 10-fold year-over-year).First, **iHealth Labs (JiuAn Medical)** is expected to see its H1 net profit surge by over 120 times, primarily driven by strong overseas demand for its COVID-19 antigen test kits and improved cost controls. Second, **Tianqi Lithium** forecasts a roughly 35-fold profit increase, benefiting from sustained high lithium prices and expanded production capacity—highlighting the robust momentum in upstream new energy materials. Third, **Tongwei Co., Ltd.** anticipates over a 10-fold profit jump, supported by booming demand across the photovoltaic supply chain and dual growth from its polysilicon and solar cell businesses.However, investors should remain cautious. While these results appear impressive, some gains may stem from low base effects in the prior-year period or one-time income, which may not be sustainable. It’s essential to evaluate industry cycles, valuation levels, and long-term earnings quality. Focusing on fundamentally sound companies with stable profitability can help mitigate risks associated with short-term speculative trading.
近期，A股市场多家上市公司发布2024年半年度业绩预告，其中部分个股因净利润同比暴增引发市场高度关注。据最新披露数据，有3只个股预计净利润同比增长超过10倍，成为本轮业绩预增行情中的焦点。首先，**九安医疗**受益于海外订单持续释放及成本控制优化，预计上半年净利润同比增长超120倍，主要源于其新冠抗原检测试剂出口业务的强劲表现。其次，**天齐锂业**凭借锂价高位运行及产能释放，预计净利润同比增长约35倍，凸显新能源上游资源企业的高景气度。第三，**通威股份**在光伏产业链高需求支撑下，硅料与电池片业务双轮驱动，预计净利润同比增长超10倍。值得注意的是，尽管上述公司业绩亮眼，但投资者仍需结合行业周期、估值水平及未来增长可持续性进行综合判断。部分高增长可能源于去年同期基数较低或一次性收益，未必具备长期复制性。建议在关注高增长标的的同时，注重基本面扎实、盈利能力稳定的企业，以规避短期炒作风险。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/22481.html